Editorial: PARP inhibitors resistance: new insights in ovarian cancer therapy. [PDF]
Fiste O, Liontos M, Labidi-Galy SI.
europepmc +1 more source
Asymmetric Lip Hyperpigmentation in a Transplant Patient. [PDF]
Kimpe V +3 more
europepmc +1 more source
Unconventional superconductivity in the presence of long-range interactions in transition metal dichalcogenide moiré heterobilayers. [PDF]
Akbar W +3 more
europepmc +1 more source
Some optimization possibilities regarding the kinematics of the Geneva mechanisms
Cet article présente quelques solutions pour optimiser la cinématique des mécanismes de Malte. Ils sont présenter trois variantes des mécanismes optimisés: un mécanisme avec des chenaux curviligne, un mécanisme hybride avec de chenaux enforme de „Y” et un mécanisme de Malte classique entraîner par un mécanisme a cam.
openaire +3 more sources
Transcranial direct current stimulation (tDCS) over the dorso-lateral-prefrontal cortex in combination with exercises for the treatment of individuals with chronic low back pain (STOP-Low Back Pain Trial): study protocol for a randomised controlled trial. [PDF]
Pourchet T +5 more
europepmc +1 more source
Alternative Responses to Serious Human Rights Abuses: Of Prosecution and Trust Commissions [PDF]
Landsman, Stephan
core +1 more source
International workshop report on "Animal resilience and organismal response to environmental change: insights from basal metazoans", Tutzing (Germany), 22-25 September 2025. [PDF]
de Luca KL +3 more
europepmc +1 more source
Sarcopenia in Hospitalized Older Adults: A Cross-Sectional Study Comparing Diagnostic Thresholds and Handgrip Strength Measurement Tools. [PDF]
Hanna-Deschamps E +10 more
europepmc +1 more source
Prenatal Diagnosis of MSL2-Related Ventriculomegaly in Association With an Inherited 15q13 Microduplication. [PDF]
Zgheib O +12 more
europepmc +1 more source
Antiviral treatment in adult patients hospitalized for influenza: study protocol for a multi-center, randomized, placebo-controlled trial on the efficacy of baloxavir marboxil to reduce time to clinical improvement and the risk for severe complications (the INFLUENT trial). [PDF]
Hosszu-Fellous K +16 more
europepmc +1 more source

